ConductScience.org, home

Comparison · NCT02064868-deaths

Serelaxin + Standard of Care vs Standard of Care (SOC): deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Serelaxin + Standard of Care vs Standard of Care (SOC): deaths from any cause. Trial comparisons, record NCT02064868-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02064868-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.03640.02860.0463wilson
Risk in group 20.04810.03590.0642wilson
Risk difference, group 1 minus group 2-0.0117-0.02950.00405newcombe hybrid score
Risk ratio, group 1 over group 20.7580.5181.11log
Odds ratio, group 1 over group 20.7480.5031.11log
Number needed to treat, for one fewer death from any cause on Serelaxin + Standard of Care than on Standard of Care (SOC)85.8from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: standard of care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Serelaxin + Standard of CareSerelaxin (30 μg/kg/day) as continuous 48 hour intravenous infusion plus standard of care.631,729EG000
Group 2Standard of Care (SOC)
All patients were required to receive standard of care background heart failure (HF) management during the study, according to local guidelines/international standards. This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
43894EG001

Harm

What it counts
Total, all-cause mortality
Time frame
All Cause Mortality: 30 days (additional deaths are included which occurred after the clinical trial reporting period of 30 days for up to 8 months post randomization); Serious Adverse Events: 14 days; Other non-serious Adverse Events (AEs): 5 days

Source ClinicalTrials.gov

Trial

Title
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
NCT number
NCT02064868
Phases
PHASE3
Conditions
Acute Heart Failure (AHF)
Interventions
Serelaxin, Standard of Care
Lead sponsor
Novartis Pharmaceuticals
Results first posted
2019-03-22

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02064868-deaths